Tiragolumab
Based on 1 Customer Validation
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.
For research use only. We do not sell to patients.
- Purity: 99.04%
- CAS No.: 1918185-84-8
- Molecular Weight:148.66 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
TIGIT
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Tiragolumab has a significant ADCP effect on CHO-K1/TIGIT cells in a dose-dependent manner.The EC50 for this effect is 189.43 ng/mL.
Chemical Information
-
CAS No. 1918185-84-8
-
Appearance Liquid
-
Molecular Weight 148.66 kDa
-
Color Colorless to light yellow
-
SMILES
[Tiragolumab]
-
Synonyms
MTIG-7192A; RG-6058
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Houssaini MS, et al. Advances in the management of non-small cell lung cancer (NSCLC): A new practice changing data from asco 2020 annual meeting. Cancer Treat Res Commun. 2020;25:100239. [Content Brief]
[2]. Caruso C. Tiragolumab Impresses in Multiple Trials. Cancer Discov. 2020 Aug;10(8):1086-1087. [Content Brief]
[3]. Shen X, et al. TIGIT-Fc Promotes Antitumor Immunity. Cancer Immunol Res. 2021 Sep;9(9):1088-1097. [Content Brief]
[4]. Dai T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Sci Rep. 2024 May 9;14(1):10661. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz